Pattern and related factors of cognitive impairment among chronic methamphetamine users

American Journal on Addictions

Volumn 26, Issue 2, 2017, Pages 145-151

  Wang, Tong Yu ^a,b,c   Fan, Teng Teng ^a   Bao, Yan Ping ^b   Li, Xiao Dong ^d   Liang, Chun Mei ^d   Wang, Ru Jia ^b,c   Ma, Jun ^b,c   Han, Ying ^b   Meng, Shi Qiu ^b   Wu, Ping ^b   Shi, Jie ^b   Lu, Lin ^a,b  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d Zhuhai Jinding Vocabulary Rehabilitation Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE; CENTRAL STIMULANT AGENT;

ADULT; ANXIETY; ARTICLE; CHINA; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEPRESSION; EDUCATIONAL STATUS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; PREVALENCE; PSYCHOSIS; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; DRUG DEPENDENCE; INTELLIGENCE TEST; ODDS RATIO; PSYCHOLOGY; QUESTIONNAIRE; STATISTICAL MODEL;

ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; CHINA; COGNITIVE DYSFUNCTION; EDUCATIONAL STATUS; FEMALE; HUMANS; INTELLIGENCE TESTS; LOGISTIC MODELS; MALE; METHAMPHETAMINE; ODDS RATIO; PREVALENCE; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 85011990307     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12505     Document Type: Article

References (35)

1. Degenhardt L, Baker A, Maher L. Methamphetamine: Geographic areas and populations at risk, and emerging evidence for effective interventions. Drug Alcohol Rev. 2008; 27:217–219.
2. United Nations Office on Drugs and Crime, 2015. World Drug Report 2015. United Nations Publication, Vienna.
3. Lu L, Fang Y, Wang X. Drug abuse in China: Past, present and future. Cell Mol Neurobiol. 2008; 28:479–490.
4. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013; 129:167–179.
5. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J Neuropsychiatry Clin Neurosci. 2003; 15:317–325.
6. Johanson CE, Frey KA, Lundahl LH, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology. 2006; 185:327–338.
7. Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev. 2007; 17:275–297.
8. Dean AC, Groman SM, Morales AM, et al. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology. 2013; 38:259–274.
9. Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012; 37:586–608.
10. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004; 10:1–14.
11. Dobkin C, Nicosia N. The war on drugs: Methamphetamine, public health, and crime. Am Econ Rev. 2009; 99:324–349.
12. Herschl LC, Highland KB, McChargue DE. Prenatal exposure to testosterone interacts with lifetime physical abuse to predict anger rumination and cognitive flexibility among incarcerated methamphetamine users. Am J Addict. 2012; 21:363–369.
13. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53:695–699.
14. Copersino ML, Fals-Stewart W, Fitzmaurice G, et al. Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol. 2009; 17:337–344.
15. Guo JX. A preliminary application of the Montreal Cognitive Assessment chinese version. Chin Acad Med Sci. 2011; 12:35 (in Chinese).
16. Cohen JB, Dickow A, Horner K, et al. Abuse and violence history of men and women in treatment for methamphetamine dependence. Am J Addict. 2003; 12:377–385.
17. Bao YP, Qiu Y, Yan SY, et al. Pattern of drug use and depressive symptoms among amphetamine type stimulants users in Beijing and Guangdong province, China. PLoS ONE. 2013; 8:e60544.
18. Eslami-Shahrbabaki M, Fekrat A, Mazhari S. A study of the prevalence of psychiatric disorders in patients with methamphetamine-induced psychosis. Addict Health. 2015; 7:37–46.
19. McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry. 2013; 70:319–324.
20. Wang Z, Yuan CM, Huang J, et al. Reliability and validity of Beck depression inventory in Chinese patients with depression. Chin J Psychiatry 2011; 25:476–480.
21. Tang YH. Hamilton anxiety rating scale. Shanghai Arch Psychiatry. 1984; 2:64–65.
22. Si TM, Yan JZ, Shu L, et al. The reliability and validity of the positive and negative symptom scale (PANSS, Chinese version). Chin J Psychiatry. 2004; 18:45–47.
23. Simon SL, Domier C, Carnell J, et al. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000; 9:222–231.
24. Herbeck DM, Brecht ML. Substance use and mental health characteristics associated with cognitive functioning among adults who use methamphetamine. J Addict Dis. 2013; 32:11–25.
25. Price KL, DeSantis SM, Simpson AN, et al. The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict. 2011; 20:447–455.
26. Harrell PT, Mancha BE, Martins SS, et al. Cognitive performance profiles by latent classes of drug use. Am J Addict. 2014; 23:431–439.
27. Booth BM, Leukefeld C, Falck R, et al. Correlates of rural methamphetamine and cocaine users: Results from a multistate community study. J Stud Alcohol. 2006; 67:493–501.
28. O'Malley S, Adamse M, Heaton RK, et al. Neuropsychological impairment in chronic cocaine abusers. Am J Drug Alcohol Abuse. 1992; 18:131–144.
29. Nie H, Xu Y, Liu B, et al. The prevalence of mild cognitive impairment about elderly population in China: A meta-analysis. Int J Geriatr Psychiatry. 2011; 26:558–563.
30. Sofuoglu M, DeVito EE, Waters AJ, et al. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013; 64:452–463.
31. Craik FI, Bialystok E. Cognition through the lifespan: Mechanisms of change. Trends Cogn Sci. 2006; 10:131–138.
32. Chen CK, Lin SK, Chen YC, et al. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend. 2015; 148:158–164.
33. Ornstein TJ, Iddon JL, Baldacchino AM, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000; 23:113–126.
34. Rossetti HC, Lacritz LH, Cullum CM, et al. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2011; 77:1272–1275.
35. Copersino ML, Schretlen DJ, Fitzmaurice GM, et al. Effects of cognitive impairment on substance abuse treatment attendance: Predictive validation of a brief cognitive screening measure. Am J Drug Alcohol Abuse. 2012; 38:246–250.